Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis

American Journal of Clinical Dermatology

Volumn 13, Issue 2, 2012, Pages 113-123

  Frankel, Hillary C ^a   Qureshi, Abrar A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atopic dermatitis; Calcineurin inhibitors; Corticosteroids; Pimecrolimus; Tacrolimus

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; COLLAGEN; CORTICOSTEROID; CYCLOSPORIN; EMOLLIENT AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHODIESTERASE INHIBITOR; PIMECROLIMUS; PSORALEN; TACROLIMUS; THALIDOMIDE; TRANSCRIPTION FACTOR NFAT;

ACNE; ALCOHOL INTOLERANCE; ANAPHYLAXIS; ANTIMICROBIAL THERAPY; APPLICATION SITE REACTION; ATOPIC DERMATITIS; CANCER RISK; CASE CONTROL STUDY; COLLAGEN SYNTHESIS; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DISEASE CONTROL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; ERYTHEMA; HERPES SIMPLEX; HUMAN; HYPERESTHESIA; HYPOPIGMENTATION; INFECTION; INFECTION RISK; INSULIN RESISTANCE; KAPOSI VARICELLIFORM ERUPTION; LYMPHOMA; MAST CELL; MENTAL HEALTH; OUTCOME ASSESSMENT; PAIN; PERIORAL DERMATITIS; PHOTOAGING; PHOTOTHERAPY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN IRRITATION; SKIN TINGLING; STRIA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TACHYPHYLAXIS; TARGET CELL; TELANGIECTASIA; TREATMENT DURATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; XEROSIS;

EID: 84856624312     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11597780-000000000-00000     Document Type: Review

References (44)

1. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003 Jan 11; 361 (9352): 151-60 (Pubitemid 36092023)
2. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol 2004 Mar; 50 (3): 391-404
3. US FDA. New drug application 21-202 approval letter [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21-302- ELIDEL-Approv.pdf [Accessed 2011 Apr 3]
4. US FDA. New drug application 50-777 approval letter [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2000/ 50777ltr.pdf [Accessed 2011 Apr 3]
5. Van Leent EJ, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998 Jul; 134 (7): 805-9 (Pubitemid 28350183)
6. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the longterm management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205 (3): 271-7
7. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis: European Tacrolimus Multicenter Atopic Dermatitis Study Group. New Engl J Med 1997 Sep 18; 337 (12): 816-21 (Pubitemid 27391631)
8. Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009 Aug; 129 (8): 1892-908
9. Leung DY, Hanifin JM, Charlesworth EN, et al. Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 1997 Sep; 79 (3): 197-211
10. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin 2010 Mar; 26 (3): 633-40
11. Tomi NS, Luger TA. The treatment of atopic dermatitis with topical immunomodulators. Clin Dermatol 2003 May-Jun; 21 (3): 215-24 (Pubitemid 36629333)
12. Akhavan A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 2003 May-Jun; 21 (3): 225-40 (Pubitemid 36629334)
13. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005; 6 (2): 65-77 (Pubitemid 40529749)
14. Abramovits W, Fleischer Jr AB, Jaracz E, et al. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. J Drugs Dermatol 2008 Dec; 7 (12): 1153-8
15. Fleischer Jr AB, Abramovits W, Breneman D, et al. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatol Treat 2007; 18 (3): 151-7 (Pubitemid 46854833)
16. Paller AS, Lebwohl M, Fleischer Jr AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005 May; 52 (5): 810-22 (Pubitemid 40614645)
17. Mandelin J, Remitz A, Virtanen H, et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol 2010 Mar; 90 (2): 170-4
18. Doss N, Reitamo S, Dubertret L, et al. Superiority of tacrolimus 0.1%ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol 2009 Aug; 161 (2): 427-34
19. Neumann E, Amtage D, Bruckner-Tuderman L, et al. A single-center openlabel long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. J Dtsch Dermatol Ges 2008 Jul; 6 (7): 548-53 (Pubitemid 351871993)
20. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, doubleblind, controlled study of long-term treatment with 0.1%tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005 Jun; 152 (6): 1282-9 (Pubitemid 40933430)
21. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002 Mar; 109 (3): 547-55 (Pubitemid 34234209)
22. FK506 Ointment Study Group. Phase III comparative study of FK506 ointment versus betamethasone valerate ointment in atopic dermatitis (trunk/extremities) [in Japanese]. Nishinihon J Derm 1997; 59: 870-9
23. FK506 Ointment Study Group. Phase III comparative study of FK506 ointment versus alclometasone dipropionate ointment in atopic dermatitis (face/neck) [in Japanese]. Hihuka Kiyo [Dermatology Bulletin] 1997; 92: 277-82
24. Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1%and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004 Jun; 15 (3): 169-78 (Pubitemid 39214578)
25. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br JDermatol 2001Apr; 144 (4): 788-94 (Pubitemid 32374782)
26. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol 2006 May; 142 (5): 633-7 (Pubitemid 43727555)
27. US FDA. FDA approves updated labeling with boxed warning and medication guide for two eczema drugs, Elidel and Protopic [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm153941.htm [Accessed 2011 Nov 21]
28. Bieber T. Atopic dermatitis. Ann Dermatol 2010 May; 22 (2): 125-37
29. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007 Apr; 127 (4): 808-16 (Pubitemid 46434650)
30. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004 May; 15 (4): 419-28 (Pubitemid 38988028)
31. Soderberg KC, Hagmar L, Schwartzbaum J, et al. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 2004 Nov 4; 4: 51
32. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214 (4): 289-95 (Pubitemid 46659010)
33. Hashizume H, Yagi H, Ohshima A, et al. Comparable risk of herpes simplex virus infection between topical treatments with tacrolimus and corticosteroids in adults with atopic dermatitis. Br J Dermatol 2006 Jun; 154 (6): 1204-6 (Pubitemid 43727410)
34. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998 Sep; 111 (3): 396-8 (Pubitemid 28400083)
35. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001 Mar; 144 (3): 507-13 (Pubitemid 32232004)
36. Poole CD, Chambers C, Allsopp R, et al. Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. J Eur Acad Dermatol Venereol 2010 Jun; 24 (6): 674-8
37. Burkhart CN, Burkhart CG. Pilot study of patient satisfaction with nonfluorinated topical steroids compared with a topical immunomodulator in atopiform dermatitis. Int J Dermatol 2004 Mar; 43 (3): 215-9 (Pubitemid 38425673)
38. Taneja C, Antaya RJ, BergerA, et al. Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis. J Drugs Dermatol 2010 Apr; 9 (4): 372-6
39. Delea TE, Gokhale M, Makin C, et al. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. J Manag Care Pharm 2007 May; 13 (4): 349-59 (Pubitemid 46964282)
40. Hjelmgren J, Svensson A, Jorgensen ET, et al. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol 2007 May; 156 (5): 913-21 (Pubitemid 46642804)
41. Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003 Apr; 48 (4): 553-63 (Pubitemid 36397019)
42. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006 Jun; 154 (6): 1137-46 (Pubitemid 43727397)
43. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practicalmeasure for routine clinical use. Clin ExpDermatol 1994May; 19 (3): 210-6 (Pubitemid 24194579)
44. Whalley D, McKenna SP, Dewar AL, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatology 2004 Feb; 150 (2): 274-83 (Pubitemid 38352465)